Cabaletta Bio (CABA) Capital Expenditures (2019 - 2025)
Cabaletta Bio's quarterly Capital Expenditures came in at -$1.0 million in Q4 2025, down 372.34% year-on-year from $376000.0 in Q4 2024, and down 204.38% quarter-over-quarter from $981000.0 in Q3 2025.
Cabaletta Bio has reported Capital Expenditures for 7 years, with the latest figure at -$1.0 million in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 372.34% year-over-year to -$1.0 million; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (down 31.2% YoY), and the FY2024 full-year result was $2.2 million, up 214.96% from the prior year.
- Capital Expenditures for Q4 2025 stood at -$1.0 million, down from $981000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.7 million in Q3 2022, with the low at -$2.1 million in Q4 2022.
- Average Capital Expenditures over 5 years is $214684.2, with a median of $200000.0 recorded in 2023.
- Peak annual rise in Capital Expenditures reached 2146.15% in 2024, while the deepest fall reached 603.51% in 2024.
- Tracing CABA's Capital Expenditures over 5 years: stood at $1.1 million in 2021, then slumped by 296.06% to -$2.1 million in 2022, then surged by 109.36% to $200000.0 in 2023, then surged by 88.0% to $376000.0 in 2024, then slumped by 372.34% to -$1.0 million in 2025.
- The last three Capital Expenditures figures came in at -$1.0 million (Q4 2025), $981000.0 (Q3 2025), and $43000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.02 Mn |
| Dec 31, 2025 | -1.02 Mn |
| Sep 30, 2025 | 981,000.00 |
| Sep 30, 2025 | 981,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | -287,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 57,000.00 |
| Jun 30, 2023 | 57,000.00 |
| Mar 31, 2023 | 380,000.00 |
| Mar 31, 2023 | 380,000.00 |
| Dec 31, 2022 | -2.14 Mn |
| Dec 31, 2022 | -2.14 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 269,000.00 |
| Jun 30, 2022 | 269,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | -409,000.00 |
| Sep 30, 2021 | -409,000.00 |
| Jun 30, 2021 | 109,000.00 |
| Jun 30, 2021 | 109,000.00 |
| Mar 31, 2021 | 376,000.00 |
| Mar 31, 2021 | 376,000.00 |
| Dec 31, 2020 | 227,000.00 |
| Dec 31, 2020 | 227,000.00 |
| Sep 30, 2020 | 162,000.00 |
| Sep 30, 2020 | 162,000.00 |
| Jun 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 20,000.00 |
| Mar 31, 2020 | 226,000.00 |
| Mar 31, 2020 | 226,000.00 |
| Dec 31, 2019 | 52,000.00 |
| Dec 31, 2019 | 52,000.00 |
| Sep 30, 2019 | -206,000.00 |
| Sep 30, 2019 | -206,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Mar 31, 2019 | 180,000.00 |
| Mar 31, 2019 | 180,000.00 |